Seminar by Dr. Francesco de Rubertis, MedicXi // Venture capital investing in early stage life sciences

Learn how a Venture Capital can fund and support high potential scientists and early translational technologies, on their path towards development.

The seminar by Dr. Francesco de Rubertis will be followed by 1-on-1 workshop with Francesco, and probably other Industry experts, where EPFL  members can pitch their translational project (on Doodle registration until  25.03.2019 at https://epfl.doodle.com/poll/k2pyewrz4q9p74md)

This seminar is in the frame of  the 1st C4L Translational Innovation Evening; A bi-monthly series of informal events where researchers of the EPFL School of Life Sciences can pitch and discuss their early stage translational project with senior industry experts.

MedicXi is a Venture Capital firm,  equally comfortable to invest at a very early-stage of drug development, when candidate drugs have just been discovered and are entering preclinical stage, as at later stages of clinical development.

Francesco is a co-founder and Partner at Medicxi. Prior to Medicxi, Francesco was a partner at Index Ventures for 19 years, having joined the firm in 1997 to launch its life sciences practice. Under his leadership, the asset-centric approach to life sciences investing was conceived and adopted. Francesco currently serves on the boards of a number of portfolio companies, including Janpix and Critical Pressure.   Francesco’s prior investments include CellZome (acquired by GlaxoSmithKline), GenMab (Copenhagen: GEN.CO), GenSight Biologics (Euronext: SIGHT), Micromet (acquired by Amgen), Minerva Neurosciences (NASDAQ:NERV), Molecular Partners (Swiss:MOLN.SW), PanGenetics (acquired by Abbott), Parallele Biosciences (acquired by Affymetrix), Profibrix (acquired by The Medicines Company), Versartis (NASDAQ:VSAR). Francesco received a BA in Genetics and Microbiology from the University of Pavia and a PhD Molecular Biology from the University of Geneva. He conducted postdoctoral research at the Whitehead Institute at MIT and is a CFA Charterholder. Francesco also serves on the strategic advisory board of the University of Geneva.